Castle Study Shows Boosted Reyataz(R) (Atazanavir) Is A Well Tolerated And Effective Option For Treatment-Naïve Patients
Feb 13th 2008Drug InformationClinical Trials
The week-48 results of the CASTLE study were announced at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) and showed boosted atazanavir to be as efficacious in antiretroviral-naive HIV-1 patients as lopinavir/ritonavir.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
